Clinical Trials · NCT06305598
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
- Phase
- Phase 1
- Recruitment status
- Recruiting
- Sponsor
- Roswell Park Cancer Institute
- Enrollment
- 14
- Start date
- Dec 2024
- Locations
- 1 site, United States
- Primary endpoint
- Androgen receptor (AR) activity